Clinical Trials Directory

Trials / Sponsors / KAI Pharmaceuticals

KAI Pharmaceuticals

Industry · 10 registered clinical trials.

StatusTrialPhaseStarted
TerminatedOpen-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-41
Secondary Hyperparathyroidism
Phase 22012-03-01
CompletedEtelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mine
Secondary Hyperparathyroidism
Phase 22011-12-05
CompletedSafety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism
Secondary Hyperparathyroidism
Phase 22011-02-20
CompletedSafety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparath
Hyperparathyroidism, Secondary
Phase 12010-09-07
CompletedSafety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
Hyperparathyroidism, Secondary
Phase 12010-06-09
CompletedSafety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury
Spinal Cord Injury
Phase 22009-03-01
CompletedSafety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia
Postherpetic Neuralgia
Phase 22009-03-01
CompletedSafety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
Pain, Postoperative
Phase 22008-12-01
CompletedSafety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes
Phase 22008-11-01
CompletedSafety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Myocardial Infarction
Phase 1 / Phase 22004-09-01